title: [The therapeutic efficacy of interferon-alfa-2a (Roferon-A) in chronic hepatitis C].
abstract: OBJECTIVE
  Evaluation of 6-month treatment with roferon-A of patients with chronic hepatitis C (CHC) and comparison of the treatment regimens.
  
  
  METHODS
  79 CHC patients received roferon-A for 3 months in a dose 6,000,000 IU 3 time a week. In case of the response to treatment was continued for the next 3 months (3,000,000 IU 3 times a week). Clinical-laboratory findings, results, of EIA and liver biopsy histology were examined.
  
  
  RESULTS
  Primary remission was achieved in 71.8% of cases. 36.9% of patients developed recurrences including 14.1% recurrence arising in the course of therapy. Stable remission was obtained in 32.4% of patients. 28.2% patients were non-responders. Side effects were mild, discontinuation of the treatment was necessary only in 7% of cases.
  
  
  CONCLUSIONS
  Roferon-A administration in a dose 6,000,000 IU for 24 weeks is optimal both as related to cost and efficacy of the treatment.
authors.forename: V T
authors.initials: VT
authors.lastname: Ivashkin
authors.forename: V V
authors.initials: VV
authors.lastname: Gorbakov
authors.forename: B N
authors.initials: BN
authors.lastname: Lytsar'
authors.forename: A P
authors.initials: AP
authors.lastname: Vasil'ev
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D006526:Hepatitis C / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D018579:Patient Selection; D011379:Prognosis; D011994:Recombinant Proteins; D012074:Remission Induction; D013997:Time Factors
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins